Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vignesh T Packiam

Showing results (121-130 of 136) with videos related to

Pageof 14
Sort By:
Urologic Oncology|July 7, 2020
Long-term outcomes of incidental prostate cancer at radical cystectomyVignesh T Packiam, Matvey Tsivian, Svetlana Avulova, et al.
The Canadian Journal of Urology|April 7, 2025
Transperineal prostate biopsy without routine antibiotics demonstrates decreased infection riskBenjamin J Lichtbroun, Mann Patel, Alexis Consalvo, et al.
The Journal of Urology|March 30, 2019
Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway AnalysesNazema Y Siddiqui, Brian T Helfand, Victor P Andreev, et al.
Urologic Oncology|July 6, 2023
Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgeryRodrigo Rodrigues Pessoa, Henan Zhang, Andrew Zganjar, et al.
Urologic Oncology|July 31, 2017
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim resultsVignesh T Packiam, Donald L Lamm, Daniel A Barocas, et al.
Urologic Oncology|January 24, 2021
The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysisVignesh T Packiam, Craig V Labbate, Stephen A Boorjian, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
European Urology|July 7, 2020
Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysisStephen B Williams, Marcus G K Cumberbatch, Ashish M Kamat, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology Oncology|April 26, 2025
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder CancerVignesh T Packiam, Ian M McElree, Saum Ghodoussipour, et al.
Pageof 14

Showing results (121-130 of 136) with videos related to

Sort By:
Pageof 14
Urologic Oncology|July 7, 2020
Long-term outcomes of incidental prostate cancer at radical cystectomyVignesh T Packiam, Matvey Tsivian, Svetlana Avulova, et al.
The Canadian Journal of Urology|April 7, 2025
Transperineal prostate biopsy without routine antibiotics demonstrates decreased infection riskBenjamin J Lichtbroun, Mann Patel, Alexis Consalvo, et al.
The Journal of Urology|March 30, 2019
Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway AnalysesNazema Y Siddiqui, Brian T Helfand, Victor P Andreev, et al.
Urologic Oncology|July 6, 2023
Circulating antigen-primed cytotoxic T-cells in patients with renal tumors treated with surgeryRodrigo Rodrigues Pessoa, Henan Zhang, Andrew Zganjar, et al.
Urologic Oncology|July 31, 2017
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim resultsVignesh T Packiam, Donald L Lamm, Daniel A Barocas, et al.
Urologic Oncology|January 24, 2021
The association of salvage intravesical therapy following BCG with pathologic outcomes and survival after radical cystectomy for patients with high-grade non-muscle invasive bladder cancer: A multi-institution analysisVignesh T Packiam, Craig V Labbate, Stephen A Boorjian, et al.
Urologic Oncology|June 7, 2021
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCGRyan L Steinberg, Vignesh T Packiam, Lewis J Thomas, et al.
European Urology|July 7, 2020
Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysisStephen B Williams, Marcus G K Cumberbatch, Ashish M Kamat, et al.
European Urology|October 4, 2025
Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the BladderAmanda A Myers, Ruchika Talwar, Zhigang Duan, et al.
European Urology Oncology|April 26, 2025
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder CancerVignesh T Packiam, Ian M McElree, Saum Ghodoussipour, et al.
Pageof 14